The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
A randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of AD-115A and the administration of AD-1151 for healthy subjects in fasting state
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
46
Single-dose oral administration of AD-115A or AD-1151 (200 mg tablet), according to randomized sequence.
H PLUS YANGJI HOSPITAL, Seoul
Seoul, South Korea
RECRUITINGMaximum concentration of drug in plasma (Cmax)
Cmax of AD-115A
Time frame: pre-dose to 24 hours
Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-115A
Time frame: pre-dose to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.